https://pharmadog.xyz/news/385223 pharmadog en 2026-09-09T19:46:00.000Z Tyra Biosciences’ bladder cancer pill misses expected response rate in Phase 2 trial https://pharmadog.xyz/news/384607 pharmadog en 2026-09-09T17:47:06.000Z Encoded Therapeutics raises $275 million in Series F round for Dravet syndrome program https://pharmadog.xyz/news/384608 pharmadog en 2026-09-09T17:44:20.000Z ARPA-H selects UpDoc, Tempus AI and Atman Health for new AI heart-disease program https://pharmadog.xyz/news/384499 pharmadog en 2026-09-09T16:51:11.000Z Researchers urge FDA to adopt EMA-style drug rejection letter disclosures https://pharmadog.xyz/news/384287 pharmadog en 2026-09-09T16:01:00.000Z ARPA-H commits $62.7 million to develop FDA-authorized AI for heart-failure treatment https://pharmadog.xyz/news/384416 pharmadog en 2026-09-09T15:54:00.000Z Kura Oncology launches Caspian Therapeutics to develop menin-inhibitor diabetes drug with $50M funding https://pharmadog.xyz/news/384223 pharmadog en 2026-09-09T15:43:28.000Z Research on orexin and narcolepsy earns Lasker Award for Yanagisawa and Mignot https://pharmadog.xyz/news/384224 pharmadog en 2026-09-09T15:35:07.000Z Compass Pathways reports positive one-year data for its psilocybin therapy COMP360 https://pharmadog.xyz/news/384179 pharmadog en 2026-09-09T15:04:00.000Z FDA appoints permanent heads of CDER and CBER, adding AI deputy role https://pharmadog.xyz/news/384159 pharmadog en 2026-09-09T14:58:55.000Z AI cannot solve emergency-room woes, highlighting broader health-care challenges https://pharmadog.xyz/news/383992 pharmadog en 2026-09-09T13:56:42.000Z Webinar explores how GLP-1 obesity drugs are reshaping US healthcare and market dynamics https://pharmadog.xyz/news/384011 pharmadog en 2026-09-09T13:38:20.000Z Scientists who discovered orexin receive Lasker Award as FDA appoints permanent heads of key drug and biologics centers https://pharmadog.xyz/news/384012 pharmadog en 2026-09-09T13:15:57.000Z AstraZeneca's COPD drug cuts flare-ups in late-stage trials, offering new option for patients https://pharmadog.xyz/news/383864 pharmadog en 2026-09-09T13:00:53.000Z Sandoz to invest $1 billion in European biosimilar hub, targeting 100 biosimilars by 2040 https://pharmadog.xyz/news/383865 pharmadog en 2026-09-09T12:05:41.000Z Novo Nordisk halts two IL-6 heart trials as Novartis suffers Phase 3 setbacks; Ionis wins first Alexander disease approval https://pharmadog.xyz/news/383716 pharmadog en 2026-09-09T12:00:42.000Z FDA makes acting CBER and CDER heads permanent, signaling leadership continuity https://pharmadog.xyz/news/383717 pharmadog en 2026-09-09T11:56:16.000Z BMS reports positive mid-stage results for arlo-cel in heavily pre-treated myeloma patients https://pharmadog.xyz/news/383607 pharmadog en 2026-09-09T11:53:36.000Z Telemedicine firm begins offering GLP-1 medications to treat addiction https://pharmadog.xyz/news/123087 pharmadog en 2026-09-09T11:38:00.000Z BioSpace launches dashboard to track performance of U.S. biotech IPOs in 2026 https://pharmadog.xyz/news/383455 pharmadog en 2026-09-09T11:01:41.000Z NodThera rebrands as Rezera and targets Phase 3 trial in 2027 https://pharmadog.xyz/news/383479 pharmadog en 2026-09-09T11:01:00.000Z Solstice Oncology secures $225M Series A to launch FDA-cleared Phase 2 CTLA-4 antibody trial https://pharmadog.xyz/news/383456 pharmadog en 2026-09-09T11:00:54.000Z TwoStep Therapeutics raises $62.5 million Series A backed by Pfizer and Merck KGaA venture groups https://pharmadog.xyz/news/383457 pharmadog en 2026-09-09T11:00:49.000Z Kura Oncology spins out diabetes program into new company with $50M funding and Lilly support https://pharmadog.xyz/news/383458 pharmadog en 2026-09-09T11:00:48.000Z Beeline Medicines reports promising Phase 2 lupus data https://pharmadog.xyz/news/383459 pharmadog en 2026-09-09T11:00:08.000Z Tyra Biosciences reports Phase 2 success in low-risk bladder cancer, plans pivotal trial https://pharmadog.xyz/news/383499 pharmadog en 2026-09-09T11:00:00.000Z Caspian Therapeutics launches with $50M to develop menin inhibitors for diabetes and cardiometabolic disease https://pharmadog.xyz/news/383519 pharmadog en 2026-09-09T11:00:00.000Z Solstice Oncology secures $225M Series A to advance CTLA-4 antibody porustobart in colon cancer https://pharmadog.xyz/news/383480 pharmadog en 2026-09-09T11:00:00.000Z Caspian Therapeutics launches with $50M funding and Eli Lilly backing to develop menin inhibitor for diabetes https://pharmadog.xyz/news/384091 pharmadog en 2026-09-09T09:45:00.000Z Luma Group closes $410 million, 15-year life-science venture fund https://pharmadog.xyz/news/384092 pharmadog en 2026-09-09T09:43:00.000Z Encoded Therapeutics secures $275M Series F to push Dravet gene therapy and expand manufacturing https://pharmadog.xyz/news/383922 pharmadog en 2026-09-09T09:15:00.000Z Tyra Biosciences reports phase 2 bladder cancer data, complete response rates miss analyst targets, shares slide https://pharmadog.xyz/news/383924 pharmadog en 2026-09-09T09:01:00.000Z FDA appoints permanent heads for CDER and CBER amid pending commissioner confirmation https://pharmadog.xyz/news/384090 pharmadog en 2026-09-09T08:56:00.000Z Kura Oncology launches Caspian Therapeutics with $50M funding to develop next-generation diabetes drug https://pharmadog.xyz/news/383224 pharmadog en 2026-09-09T08:30:00.000Z AMA chief says AI will augment, not replace, physicians https://pharmadog.xyz/news/383225 pharmadog en 2026-09-09T08:30:00.000Z AI tools struggle to improve emergency room workflow, study finds https://pharmadog.xyz/news/383223 pharmadog en 2026-09-09T08:30:00.000Z Opinion: Autonomous AI could surpass AI-assisted doctors on key tasks by 2030 https://pharmadog.xyz/news/384335 pharmadog en 2026-09-09T08:11:00.000Z Abbott receives FDA clearance for TactiFlex Duo catheter, offering flexible AFib ablation options https://pharmadog.xyz/news/383011 pharmadog en 2026-09-09T07:38:48.000Z Evommune's MRGPRX2 antagonist fails second Phase 2b trial in atopic dermatitis https://pharmadog.xyz/news/382927 pharmadog en 2026-09-09T07:00:00.000Z Career setbacks offer data points, not definitive verdicts, says executive coach https://pharmadog.xyz/news/383430 pharmadog en 2026-09-09T04:23:00.000Z Beeline's oral lupus drug afimetoran meets primary endpoint in Phase 2, paving way for Phase 3 https://pharmadog.xyz/news/382543 pharmadog en 2026-09-09T04:20:00.000Z Biopharma looks beyond China to five alternative overseas markets amid rising geopolitical tensions https://pharmadog.xyz/news/382544 pharmadog en 2026-09-09T04:10:00.000Z Biotech crossover rounds projected to exceed $4.2 billion in 2026, supporting IPO pipeline https://pharmadog.xyz/news/383262 pharmadog en 2026-09-09T04:06:00.000Z Evommune gives up hope for MRGPRX2 antagonist to treat itch after latest phase 2 fail https://pharmadog.xyz/news/383923 pharmadog en 2026-09-09T02:05:00.000Z Labcorp acquires MLM Medical Labs to expand global lab network across four continents https://pharmadog.xyz/news/383432 pharmadog en 2026-09-09T00:08:00.000Z Solstice Oncology raises $225M Series A to push next-gen CTLA-4 antibody into Phase 2 colon cancer trial https://pharmadog.xyz/news/381628 pharmadog en 2026-09-08T23:00:00.000Z Six AI agents run on a deskside system to deliver on-premises clinical decision support https://pharmadog.xyz/news/381371 pharmadog en 2026-09-08T21:15:40.000Z FDA makes permanent four key leadership appointments, including first AI deputy commissioner https://pharmadog.xyz/news/381200 pharmadog en 2026-09-08T21:07:50.000Z FDA makes CBER and CDER leaders permanent amid pending commissioner confirmation https://pharmadog.xyz/news/381421 pharmadog en 2026-09-08T19:31:00.000Z FreshPoint recalls 1,093 Cranberry Chicken Salad Sandwiches over undeclared egg allergen https://pharmadog.xyz/news/381244 pharmadog en 2026-09-08T18:41:00.000Z Roivant reports record-breaking Phase 2 results for PH-ILD drug mosliciguat, starts Phase 3 https://pharmadog.xyz/news/380855 pharmadog en 2026-09-08T18:29:02.000Z Pharvaris reports injectable-like efficacy from once-daily oral pill for rare genetic disease https://pharmadog.xyz/news/380579 pharmadog en 2026-09-08T17:53:52.000Z Amgen reports positive lung cancer trial results for Imdelltra combined with checkpoint inhibitor https://pharmadog.xyz/news/380672 pharmadog en 2026-09-08T17:38:59.000Z FDA halts US shipments from Shoolin Pharma after unsanitary inspection findings https://pharmadog.xyz/news/380580 pharmadog en 2026-09-08T17:19:19.000Z Tech giants and health apps push users to link medical records for personalized services https://pharmadog.xyz/news/380471 pharmadog en 2026-09-08T16:24:59.000Z Sanofi presents detailed asthma trial data while AstraZeneca reports positive COPD results at ERS 2026 https://pharmadog.xyz/news/380303 pharmadog en 2026-09-08T15:56:33.000Z Anthropic hires corporate development lead to drive biopharma acquisitions and partnerships https://pharmadog.xyz/news/380407 pharmadog en 2026-09-08T15:52:00.000Z Moonwalk Biosciences raises $70M and pivots to RNAi obesity drug development https://pharmadog.xyz/news/383431 pharmadog en 2026-09-08T15:46:00.000Z Schrödinger launches Tectora Therapeutics with $55 million Series A to target immunology and inflammation https://pharmadog.xyz/news/380304 pharmadog en 2026-09-08T15:21:33.000Z FDA finalizes Krazati withdrawal while Wegovy trial shows positive results in children 6-12 https://pharmadog.xyz/news/380239 pharmadog en 2026-09-08T14:51:43.000Z UnitedHealth executives donate heavily to Rep. Katherine Clark as No Surprises Act debate intensifies https://pharmadog.xyz/news/380219 pharmadog en 2026-09-08T14:50:38.000Z Inhibrx’s OX40 agonist plus Keytruda shows 48% response rate, beating Keytruda alone in head and neck cancer Phase 2 https://pharmadog.xyz/news/380220 pharmadog en 2026-09-08T14:31:40.000Z Structure Therapeutics reports oral GLP-1 weight-loss results comparable to Wegovy and strong Phase 1 amylin data https://pharmadog.xyz/news/380221 pharmadog en 2026-09-08T14:31:38.000Z Novo Nordisk halts two more late-stage heart failure trials, calling IL-6 an invalid target https://pharmadog.xyz/news/380122 pharmadog en 2026-09-08T14:22:31.000Z Democrats outline health-care priorities as they aim to retake House before November midterms https://pharmadog.xyz/news/380102 pharmadog en 2026-09-08T14:21:30.000Z Roivant's mosliciguat shows strong Phase 2 results, advancing to Phase 3 for PH-ILD https://pharmadog.xyz/news/380123 pharmadog en 2026-09-08T14:18:41.000Z Oura files for IPO after reporting $1.2 billion in earnings https://pharmadog.xyz/news/380078 pharmadog en 2026-09-08T14:14:32.000Z Sandoz announces $300 million biosimilar factory in Slovenia and plans to expand pipeline sevenfold https://pharmadog.xyz/news/379983 pharmadog en 2026-09-08T14:09:31.000Z FDA approves AstraZeneca's new breast cancer therapy https://pharmadog.xyz/news/380079 pharmadog en 2026-09-08T14:08:51.000Z Bristol Myers reports Phase 2 success for GPRC5D‑directed CAR‑T therapy https://pharmadog.xyz/news/379984 pharmadog en 2026-09-08T13:26:51.000Z Novartis' experimental drug fails pivotal trial for rare neuromuscular disease https://pharmadog.xyz/news/380408 pharmadog en 2026-09-08T13:23:20.000Z Novartis' del-desiran misses primary goal in late-stage myotonic dystrophy trial https://pharmadog.xyz/news/379811 pharmadog en 2026-09-08T13:00:00.000Z Consumer apps are turning to patient health records to expand services https://pharmadog.xyz/news/379835 pharmadog en 2026-09-08T12:27:28.000Z FDA approves AstraZeneca's oral SERD Etcamah for HR+/HER2-negative advanced breast cancer https://pharmadog.xyz/news/379687 pharmadog en 2026-09-08T12:05:40.000Z Novartis' $12 billion Avidity drug fails Phase 3 trial in myotonic dystrophy https://pharmadog.xyz/news/379688 pharmadog en 2026-09-08T12:01:00.000Z Moonwalk Biosciences raises $70M to move RNAi obesity drug MW101 toward first-in-human trials in 2027 https://pharmadog.xyz/news/379643 pharmadog en 2026-09-08T12:00:17.000Z Moonwalk Biosciences raises $70M to advance siRNA obesity therapy https://pharmadog.xyz/news/379689 pharmadog en 2026-09-08T11:56:16.000Z Novartis' pelacarsen fails Phase 3, casting doubt on Lp(a) lowering strategy https://pharmadog.xyz/news/379707 pharmadog en 2026-09-08T11:45:00.000Z AstraZeneca’s experimental COPD drug tozorakimab cuts flare-ups by 30% in Phase 3 trials https://pharmadog.xyz/news/379708 pharmadog en 2026-09-08T11:32:23.000Z Administrative gap stalls access to new pancreatic cancer therapy https://pharmadog.xyz/news/379644 pharmadog en 2026-09-08T11:30:32.000Z Inhibrx reports promising mid-stage data for OX40 agonist and plans vaccine combos early next year https://pharmadog.xyz/news/379709 pharmadog en 2026-09-08T11:30:00.000Z Inhibrx reports promising responses to OX40 immunotherapy in HPV-positive head and neck cancer https://pharmadog.xyz/news/379559 pharmadog en 2026-09-08T11:01:00.000Z BrainChild Bio secures $119M Series A to advance CAR-T therapy for deadly pediatric brain tumor https://pharmadog.xyz/news/379535 pharmadog en 2026-09-08T11:00:53.000Z BrainChild Bio raises $116 million to fund pivotal pediatric brain tumor CAR-T trial https://pharmadog.xyz/news/379536 pharmadog en 2026-09-08T11:00:21.000Z Diabetes cell-therapy firms Sernova and Seraxis announce merger https://pharmadog.xyz/news/379599 pharmadog en 2026-09-08T11:00:00.000Z BrainChild secures $116M to advance CAR-T therapies for rare pediatric brain tumors https://pharmadog.xyz/news/380279 pharmadog en 2026-09-08T10:18:00.000Z AstraZeneca’s IL-33 antibody tozorakimab earns FDA priority review after COPD trial cuts exacerbations by up to 34% https://pharmadog.xyz/news/379431 pharmadog en 2026-09-08T10:00:00.000Z Roivant's experimental pulmonary hypertension drug meets Phase 2 goals https://pharmadog.xyz/news/379367 pharmadog en 2026-09-08T10:00:00.000Z Roivant's inhaled drug mosliciguat achieves positive Phase 2 results in interstitial lung disease https://pharmadog.xyz/news/380170 pharmadog en 2026-09-08T09:57:00.000Z FDA grants accelerated approval to AstraZeneca’s Etcamah, enabling ctDNA-guided therapy for HR-positive breast cancer https://pharmadog.xyz/news/380171 pharmadog en 2026-09-08T09:46:00.000Z Spyre Therapeutics reports positive Phase 2 results for anti-IL-23 antibody SPY003 in ulcerative colitis https://pharmadog.xyz/news/380054 pharmadog en 2026-09-08T09:29:00.000Z Pharvaris reports 83% drop in hereditary angioedema attacks in phase 3 trial, FDA decision pending https://pharmadog.xyz/news/379894 pharmadog en 2026-09-08T09:12:00.000Z BMS CAR-T therapy arlo-cel meets primary endpoint in pivotal multiple myeloma trial https://pharmadog.xyz/news/379151 pharmadog en 2026-09-08T08:30:35.000Z Beam Therapeutics reports one-year data from early-stage AATD gene therapy trial https://pharmadog.xyz/news/379195 pharmadog en 2026-09-08T08:30:00.000Z Reynolds launches fruit-flavored Vuse Pro vapes in Ohio despite lacking FDA authorization https://pharmadog.xyz/news/379200 pharmadog en 2026-09-08T08:30:00.000Z Rural hospitals seek partnership deals as Trump Medicaid cuts threaten financial stability https://pharmadog.xyz/news/379198 pharmadog en 2026-09-08T08:30:00.000Z Experts say gloves are unnecessary for flu shots, urging a shift to reduce waste https://pharmadog.xyz/news/379199 pharmadog en 2026-09-08T08:30:00.000Z Medical student speaks out against weight bias in clinical training https://pharmadog.xyz/news/379196 pharmadog en 2026-09-08T08:30:00.000Z FDA approves Revolution Medicines’ pancreatic cancer drug Rasonque, but patients face delayed access https://pharmadog.xyz/news/379197 pharmadog en 2026-09-08T08:30:00.000Z UnitedHealth executives donate over $100,000 to Rep. Katherine Clark ahead of midterms https://pharmadog.xyz/news/379152 pharmadog en 2026-09-08T08:24:44.000Z Novartis shares tumble after late-stage failure of Avidity-acquired drug https://pharmadog.xyz/news/379786 pharmadog en 2026-09-08T08:16:00.000Z Boston Scientific recalls spinal cord stimulator leads after over 1,000 serious injuries https://pharmadog.xyz/news/379047 pharmadog en 2026-09-08T07:28:55.000Z Novartis' DM1 drug del-desiran misses primary endpoint in Phase 3 HARBOR trial https://pharmadog.xyz/news/378899 pharmadog en 2026-09-08T07:00:00.000Z Benelux’s strong science base eyed for biotech scaling despite funding gaps https://pharmadog.xyz/news/378515 pharmadog en 2026-09-08T04:58:00.000Z AI can transform drug discovery only when its strengths are properly leveraged https://pharmadog.xyz/news/378516 pharmadog en 2026-09-08T04:20:00.000Z Four CDMOs to watch as biopharma outsourcing grows https://pharmadog.xyz/news/378387 pharmadog en 2026-09-08T04:09:00.000Z Moderna and Merck’s personalized mRNA cancer vaccine success spurs industry shift to faster, smaller-scale production https://pharmadog.xyz/news/378388 pharmadog en 2026-09-08T04:03:00.000Z Parkinson's drug pipeline diversifies as firms seek disease-modifying therapies https://pharmadog.xyz/news/379126 pharmadog en 2026-09-08T03:35:00.000Z Novartis' del-desiran fails primary endpoint in phase 3 Harbor trial for myotonic dystrophy type 1 https://pharmadog.xyz/news/380053 pharmadog en 2026-09-08T00:22:00.000Z Inhibrx reports 9.6-month median PFS for OX40 agonist combo in phase 2 head-neck cancer trial https://pharmadog.xyz/news/381441 pharmadog en 2026-09-08T00:00:00.000Z EMA publishes guidance on voluntary electronic product information submissions for EU MAAs https://pharmadog.xyz/news/381442 pharmadog en 2026-09-08T00:00:00.000Z FDA approves AstraZeneca breast cancer drug despite negative advisory committee vote; Novartis faces cholesterol drug setbacks